Table of Contents
Lung Cancer International
Volume 2015, Article ID 545601, 7 pages
http://dx.doi.org/10.1155/2015/545601
Research Article

Usefulness of Ki-67, Mitoses, and Tumor Size for Predicting Metastasis in Carcinoid Tumors of the Lung: A Study of 48 Cases at a Tertiary Care Centre in Canada

1Department of Pathology, London Health Sciences Centre, Western University, London, ON, Canada
2Department of Pathology, University Hospital, 339 Windermere Road, London, ON, Canada N6A 5A5
3Brantford General Hospital, ON, Canada
4Pathologist assistant program, London Health Sciences Centre, Western University, Canada
5University of Calgary, Canada
6Division of Respirology, University of Ottawa, Canada
7Department of Thoracic Surgery, London Health Sciences Centre, Western University, London, ON, Canada

Received 29 July 2015; Accepted 7 November 2015

Academic Editor: Giovanni Luca Ceresoli

Copyright © 2015 M. G. Joseph et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. D. Travis, W. Rush, D. B. Flieder et al., “Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid,” American Journal of Surgical Pathology, vol. 22, no. 8, pp. 934–944, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Soga and Y. Yakuwa, “Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties,” Annals of Thoracic and Cardiovascular Surgery, vol. 5, no. 4, pp. 211–219, 1999. View at Google Scholar · View at Scopus
  3. G. Rindi, G. Klöppel, H. Alhman et al., “TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 449, no. 4, pp. 395–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. W. D. Travis, R. I. Linnoila, M. G. Tsokos et al., “Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases,” American Journal of Surgical Pathology, vol. 15, no. 6, pp. 529–553, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Capella, P. U. Heirz, H. Hofler, E. Solcia, and G. Kloppel, “Revised classification of neuroendocrine tumours of the lung, pancreas and gut,” Virchows Archiv, vol. 425, no. 6, pp. 547–560, 1995. View at Google Scholar · View at Scopus
  6. H. Skuladottir, F. R. Hirsch, H. H. Hansen, and J. H. Olsen, “Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark,” Lung Cancer, vol. 37, no. 2, pp. 127–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Gerdes, U. Schwab, H. Lemke, and H. Stein, “Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation,” International Journal of Cancer, vol. 31, no. 1, pp. 13–20, 1983. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Pfister, L. Moore, P. Allard et al., “Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence,” Clinical Cancer Research, vol. 5, no. 12, pp. 4079–4084, 1999. View at Google Scholar · View at Scopus
  9. D. Granberg, E. Wilander, K. Öberg, and B. Skogseid, “Prognostic markers in patients with typical bronchial carcinoid tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 9, pp. 3425–3430, 2000. View at Google Scholar · View at Scopus
  10. N. Kimura, W. Miura, T. Noshiro, Y. Miura, T. Ookuma, and H. Nagura, “Ki-67 is an indicator of progression of neuroendocrine tumors,” Endocrine Pathology, vol. 5, no. 4, pp. 223–228, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Mohsenifar, M. Almassi-Aghdam, Z. Mohammad-Taheri et al., “Prognostic values of proliferative markers ki-67 and repp86 in breast cancer,” Archives of Iranian Medicine, vol. 10, no. 1, pp. 27–31, 2007. View at Google Scholar · View at Scopus
  12. V. Costes, C. Marty-Ané, M. C. Picot et al., “Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and Kl-67-labeling study,” Human Pathology, vol. 26, no. 7, pp. 740–745, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. J. Laitinen, Y. Soini, J. Mattila, and P. Pääkkö, “Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity,” Cancer, vol. 88, no. 7, pp. 1590–1598, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. K. Arbiser, J. L. Arbiser, C. Cohen, and A. A. Gal, “Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis,” Modern Pathology, vol. 14, no. 12, pp. 1195–1199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Pelosi, J. Rodriguez, G. Viale, and J. Rosai, “Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients,” American Journal of Surgical Pathology, vol. 29, no. 2, pp. 179–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Igarashi, S.-X. Jiang, T. Kameya et al., “Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors,” Modern Pathology, vol. 17, no. 10, pp. 1259–1267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Rekhtman, “Neuroendocrine tumors of the lung: an update,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 11, pp. 1628–1638, 2010. View at Google Scholar · View at Scopus
  18. G. Pelosi, G. Rindi, W. D. Travis, and M. Papotti, “Ki-67 antigen in lung neuroendocrine tumours, unraveling a role in clinical practice,” Journal of Thoracic Oncology, vol. 9, no. 3, pp. 273–284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. E. Walts, D. Ines, and A. M. Marchevsky, “Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors,” Modern Pathology, vol. 25, no. 9, pp. 1258–1264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Rindi, C. Klersy, F. Inzani et al., “Grading the neuroendocrine tumors of the lung: an evidence-based proposal,” Endocrine-Related Cancer, vol. 21, no. 1, pp. 1–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Zahel, S. Krysa, E. Herpel et al., “Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach,” Virchows Archiv, vol. 460, no. 3, pp. 299–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Warth, L. Fink, A. Fisseler-Eckhoff et al., “Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids,” Virchows Archiv, vol. 462, no. 5, pp. 507–513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Hotta, T. Shimoda, Y. Nakanishi, and D. Saito, “Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids,” Pathology International, vol. 56, no. 10, pp. 591–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. E. Tisell, A. Oden, A. Muth et al., “The Ki67 index a prognostic marker in medullary thyroid carcinoma,” British Journal of Cancer, vol. 89, no. 11, pp. 2093–2097, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Rezanko, A. K. Akkalp, M. Tunakan, and A. A. Sari, “MIB-1 counting methods in meningiomas and agreement among pathologists,” Analytical and Quantitative Cytology and Histology, vol. 30, no. 1, pp. 47–52, 2008. View at Google Scholar · View at Scopus
  26. E. M. Leuverink, B. A. Brennan, M. L. Crook et al., “Prognostic value of mitotic counts and Ki-67 immunoreactivity in adult-type granulosa cell tumour of the ovary,” Journal of Clinical Pathology, vol. 61, no. 8, pp. 914–919, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Mir, H. Johnson Jr., R. Mathur, L. Wise, and L. B. Kahn, “Ki-67 reactivity in breast carcinoma analyzed by a computer-assisted image system: preliminary results,” Journal of the National Medical Association, vol. 87, no. 8, pp. 554–559, 1995. View at Google Scholar · View at Scopus
  28. R. Jong, A. M. Davis, M. G. Mendes, J. S. Wunder, R. S. Bell, and R. Kandel, “Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases,” Sarcoma, vol. 4, no. 1-2, pp. 47–55, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. K. E. Coleman, D. J. Brat, G. A. Cotsonis, D. Lawson, and C. Cohen, “Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance,” Applied Immunohistochemistry and Molecular Morphology, vol. 14, no. 1, pp. 109–114, 2006. View at Publisher · View at Google Scholar · View at Scopus